Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Janick Weberpals; Spyros Roumpanis; Yael Barer; Sharon Ehrlich; Nikki Jessop; Rosetta Pedotti; Adi Vaknin-Dembinsky; Livnat Brill; Gabriel Chodick; Erwan Muros Le Rouzic

doi:10.1016/j.msard.2022.104153

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Janick Weberpals, Spyros Roumpanis, Yael Barer, Sharon Ehrlich, Nikki Jessop, Rosetta Pedotti, Adi Vaknin-Dembinsky, Livnat Brill, Gabriel Chodick, Erwan Muros Le Rouzic

Research output: Contribution to journal › Letter › peer-review

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

Original language	English
Article number	104153
Journal	Multiple Sclerosis and Related Disorders
Volume	68
DOIs	https://doi.org/10.1016/j.msard.2022.104153
State	Published - Dec 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Neurology
Clinical Neurology

Access to Document

10.1016/j.msard.2022.104153

Cite this

Weberpals, J., Roumpanis, S., Barer, Y., Ehrlich, S., Jessop, N., Pedotti, R., Vaknin-Dembinsky, A., Brill, L., Chodick, G., & Rouzic, E. M. L. (2022). Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel. Multiple Sclerosis and Related Disorders, 68, Article 104153. https://doi.org/10.1016/j.msard.2022.104153

@article{fe378687e84a4eb3ad5f2ebae2648d20,

title = "Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel",

abstract = "The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7\% and 2.6\%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3\%) vs vaccinated patients (25\%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.",

author = "Janick Weberpals and Spyros Roumpanis and Yael Barer and Sharon Ehrlich and Nikki Jessop and Rosetta Pedotti and Adi Vaknin-Dembinsky and Livnat Brill and Gabriel Chodick and Rouzic, \{Erwan Muros Le\}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = dec,

doi = "10.1016/j.msard.2022.104153",

language = "الإنجليزيّة",

volume = "68",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

publisher = "Elsevier B.V.",

}

Weberpals, J, Roumpanis, S, Barer, Y, Ehrlich, S, Jessop, N, Pedotti, R, Vaknin-Dembinsky, A, Brill, L, Chodick, G & Rouzic, EML 2022, 'Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel', Multiple Sclerosis and Related Disorders, vol. 68, 104153. https://doi.org/10.1016/j.msard.2022.104153

TY - JOUR

T1 - Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods

T2 - Insights from Israel

AU - Weberpals, Janick

AU - Roumpanis, Spyros

AU - Barer, Yael

AU - Ehrlich, Sharon

AU - Jessop, Nikki

AU - Pedotti, Rosetta

AU - Vaknin-Dembinsky, Adi

AU - Brill, Livnat

AU - Chodick, Gabriel

AU - Rouzic, Erwan Muros Le

PY - 2022/12

Y1 - 2022/12

N2 - The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

AB - The coronavirus disease 2019 (COVID-19) pandemic caused challenges in the management of patients living with multiple sclerosis (PLwMS). We investigated the occurrence and severity of COVID-19 infection post-vaccination among PLwMS treated with ocrelizumab and enrolled in the Maccabi Health Services (MHS) (n = 289) or followed at the Hadassah Medical Center (HMC) (n = 80) in Israel. Most patients were fully vaccinated (MHS n = 218; HMC n = 76) and confirmed infection post-vaccination was low (3.7% and 2.6%, respectively). MHS: infection was more severe (hospitalization/intensive care unit/death) in non-vaccinated (33.3%) vs vaccinated patients (25%). HMC: one vaccinated patient required hospitalization with COVID-19 vs two unvaccinated patients. These data from two Israel cohorts suggest that occurrence of COVID-19 after mRNA vaccination is low and limited in severity.

UR - http://www.scopus.com/inward/record.url?scp=85137283210&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2022.104153

DO - 10.1016/j.msard.2022.104153

M3 - رسالة

C2 - 36081277

SN - 2211-0348

VL - 68

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

M1 - 104153

ER -

Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this